Who can take part?
Patients with previously untreated advanced triple-negative breast cancer (TNBC).
What is involved for you?
Half of all patients enrolled in this trial will receive the investigational product, and half will receive the doctors choice of chemotherapy. All medicines will be administered via an IV infusion. Each visit to the clinic will be accompanied by review by the study doctor and nurse, as well as blood collection, ECG's and physical assessments. Regular tumour assessments via scans will occur. Patients on the standard of care arm of the trial, may be given an opportunity to cross over to the experimental treatment if certain criteria are meet during the trial.